Estados Unidos · Plataformas y datos · The Motley Fool

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Publicado por The Motley Fool · Estados Unidos hace 1 h

The biotech has experienced a pullback in recent weeks.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

También te puede interesar

Lufax (NYSE:LU) Posts Quarterly Earnings Results, Misses Estimates By $11.08 EPS

Pricesmart outlines path to 63 clubs as Chile entry targets spring 2027 opening

Retail traders buy the dip on chip stocks — but Robinhood gets burned by the crypto market

FBI agent says he feared case against ex-FBI officials tied to Hunter Biden probes would look political

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Novartis Raises Guidance After Trial Setbacks Hit Profit